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I. BACKGROUND
The Committee for Japanese Standards for Antimicro-
bial SusceptibilityTesting for Bacteria, Japan Society of
Chemotherapy, (chairman: Sachiko Goto, MD, Table
1) established the standard method ofthe Japan Society
of Chemotherapy for microdilution antimicrobial sus-
ceptibility testing of bacteria that grow aerobically.!
Furthermore, the Committee (chairman: Atsushi Saito,
MD) determined the standard method for microdilution
antimicrobial susceptibility testing methods for bacte-
ria that grow anaerobically and for bacteria that require
special nutrients. 2 At the 41 st All Japan meeting for the
Japan Society of Chemotherapy (Tokyo, 1993), the
Committee proposed clinical breakpoints for antimicro-
bial agents which could be used in pulmonary infec-
tions and sepsis, soliciting opinions from the members
of the Society.The originally proposed breakpoints were
partially revised and here we submit the breakpoints in
pulmonary infections and sepsis as authorized by the
Japan Society of Chemotherapy.
It would be ideal if breakpoints for antimicrobial
agents in any organ could be determined with the meas-
urement of MIC (minimum inhibitory concentration),
a quantitative designation of drug susceptibility. The
breakpoints should be decided for each organ since con-
centration of antibiotics at each infection site differs de-
pending upon location. Breakpoints used in most of the
world comprise only one or two breakpoints, thus ne-
glecting the infection site. 3,4
The NCCLS (National Committee for Clinical
Laboratory Standards) breakpoints extensively used in
Japan5,6 were determined on the available data, such as
clinical dose and pharmacological kinetics, from Ameri-
can studies and are, therefore, not suitable for Japanese
due to differing dose schedules.The breakpoints for Japa-
nese should be investigated on the basis of the clinical
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dose in Japan (These are set by the Ministry of Health
and include maximum allowable dose).
Japan Society of Chemotherapy decided therefore to
establish the breakpoints for each infection site based
upon the clinical dose used in Japan and the concentra-
tion of the drug at the infection site for Japanese pa-
tients. In this report, we attempted to analyze the break-
points for pulmonary infections and sepsis.
II. CLINICAL BREAKPOINTS IN RESPIRATORY
TRACT INFECTIONS
1. The concept ofbreakpoints for antimicrobial agents
The term breakpoint covers a bacteriological breakpoint
that provides information regarding the in vitro sensi-
tivity of bacteria to antibiotics. It also includes a clinical
information to assist the physician to assess the clinical
response of the patient to selected agents. The break-
points in this report refer to the latter in-vivo situation.
2. Definition of the clinical breakpoint
The clinical breakpoint is defined as the MIC of antibi-
otics that is effective in more than 80% of cases, in pa-
tients with infectious diseases. The areas covered in this
report are respiratory tract infections, divided into lower
respiratory tract infections (acute pneumonia) and
chronic respiratory tract infections (CRTI). The break-
points for individual agents were determined for each
disorder. Aerobes only were considered due to insuffi-
cient clinical data for anaerobes. No further differentia-
tion among bacterial characteristics was made.
3. Approach to definition of breakpoints in
clinical cases
Cases were selected from double blind test data for new
antibiotics submitted for evaluation by various pharma-
ceutical companies. Cases were restricted to those for
which the clinical response to the agents had been de-
termined and for which the MIC against the isolated
bacteria had been measured.The proposed breakpoints
for individual antimicrobial agents were based on those
data. Tables 2 and 3 contain a partial list of these break-
points.
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Clinical Pathology
Kanto Teishin Hospital
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Tohoku University
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Table 2. Relationship between MIC against causative organisms
and clinical response (cephem antibiotics for intravenous use).
Table 3. Relationship between MIC against causative organ-
isms and clinical response (carbapenem antibiotics).
Clinical response in respiratory tract infections
MIC tug/mil -----'--------'--~-----
pneumonia (n == 339) CRTI* (n == 393) MIC {j.lg/mll
Clinical response in respiratory tract infection
pneumonia (n == 56) CRTI* (n == 119)
25/26 (96.2%)t 28/32 (87.5%)
6/7 (85.7) 3/5 (60.0)
4/4 (100) 9/11 (81.8)
4/6 (66.7) 13/13 (100)
7/7(100) 14/15(93.3)
1/1 (100) 12/14 (85.7)*
2/2 (100)* 8/12 (66.7)
5/11 (454)
0/1 (0) 0/1 (0)
1/3 (33.3)
1/2 (50.0) 0/2 (0)
:;; 0.025
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
12.5
25.0
50.0
~ 100
31/44 (70.5%)+ 52/60 (86.7%)
40/51 (78.4) 47/53 (88.7)
52/57 (91.2) 54/70 (77.1)
31/38 (81.6) 34/42 (81.0)
23/29 (79.3) 11 /14 (78.6)
25/29 (86.2) 27/33 (81.8)*
20/26 (76.9) 11 /17 (64.7)
14/17 (82.4)* 20/32 (62.5)
5/10 (50.0) 3/15 (20.0)
6/11 (54.5) 11/17 (64.7)
5/8 (62.5) 3/5 (60.0)
3/4 (75.0) 3/7 (42.9)
11/15 (73.3) 12/28 (42.9)
$ 0.025
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
12.5
25.0
~50.0
50/56 (89.3) 93/119 (73.3)
266/339 (78.5) 288/393 (73.3)
" Chronic respiratory tract infection;
t Clinical efficacy;
*Cut-off points determining the breakpoint.
4. Factors influencing clinical breakpoints
Table 4 summarizes the factors thought to influence the
clinical response to antimicrobial agents. The clinical
response of any particular agent will be influenced to a
great degree by the activity and concentration of the
antibiotic at the site of infection. In addition,
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" Chronic respiratory tract infection;
t Clinical efficacy;
*Cut-offpoints determining the breakpoint.
pharmacokinetic parameters, such as C
max
(the maxi-
mum blood concentration), TI/2 (the terminal half-life
of the drug), AUC (area under the curve: a measure of
the total amount of antibiotic present over a defined
period of time), time above the MIC and protein bind-
ing, are also important. The antimicrobial characteris-
Breakpoints in pulmonary infections and sepsis
Table 4. Factors influencing 'the clinical response to antimicrobial agents
Human pharmacokinetics
Blood concentration: Cmax' T1/2, AUC, time above the MIC, etc.
Concentration at the site (or concentration in the specimen)
in the healthy person, infected patient, pediatric patient, elderly
patient, patient with hepatic and/or renal impairment
Protein binding
Methods of measurement of drug concentration
In vitro drug characteristics
Stability of drugs (dependence on culture medium or temperature)
Factors affecting MIC: testing methods, component and pH of medium
Antimicrobial characteristics
Mechanisms of resistance
Patient factors
Compromised hosts
Severity of infection
Underlying diseases
Invasive medical devices
Table 5. Calculation pormula for breakpoints.
Breakpoint MIC =em x t X Rlr X A
where C
m
is a factor determined by Cmax;
32: Cmax > 400mglml
16 : 200 < Cmax ~ 400
8 : 50 < Cmax ~ 200
4 : 10 < Cmax ~ 50
2 : 1 < Cmax ~ 10
1 : C
max
~ 1
is a factor allOWing for half-life differences;
1 : T1/2 > 3 hr
0.5 : 1 < T1/2 ~ 3
0.25 : Tl/2 ~ 1
Rtr is a factor dependent on the ratio R (= maximum concentration at the
site /C
max
ratio);
4:' R>lO
2: 1.2 < R ~ 10
1: 0.12 < R ~ 1.2
0.5 : 0.012 < R ~ 0.12
0.25 : R ~ 0.012
A is a factor which takes into account the antimicrobial characteristics;
2 : aminoglycosides
1 : beta-Iactams (penicillins, cephems, monobactams, carbapenems)
and new-quinolones
0.5 : tetracyclines, macrolides, c1indamycins
tics of the drug (bactericidal/bacteriostatic,
'postantibiotic effect' PAE, etc.) and the condition of
the host (the defense mechanism being inhibited by
underlying disease, use of drugs, certain medical treat-
ments, etc.) should also be taken into account.
Four of these factors, Cmax (single dose), T1I2, infec-
tion site concentration and antimicrobial characteris-
tics of the drugs are considered in this report.
5. Calculation of the breakpoints
The four factors mentioned above were taken into ac-
count, and a formula was constructed to calculate a value
for the breakpoint as shown in Table 5.
6. Proposed breakpoints
The proposed breakpoints for individual antimicrobial
agents determined by the formula are listed in Tables 6
and 7. These values correlate well with the clinical re-
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Table 6. Clinical breakpoints for antimicrobial agents in respiratory tract infections (1).
Group
Penicillins
Cephems
Carbapenems
Monobactams
Drug Route Dose (g) Breakpoint MIC (,ug/mll(single) pneumonia CRTI*
ampicillin iv 1.0 2 1
piperacillin iv 2.0 2 1
ticarcillin iv 1.0 2 1
aspoxicillin iv 1.0 4 2
sulbactam / ampicillin iv 1.5 4 2
clavulanic acid /
ticarcillin iv 1.6 4 2
ampicillin po 0.5 0.5 0.125
amoxicillin po 0.25 1 0.5
cefazolin iv 1.0 4 2
cefotiam iv 1.0 4 1
cefoperazone iv 1.0 4 2
cefmenoxime iv 1.0 4 2
cefotaxime iv 1.0 2 0.5
ceftizoxime iv 1.0 4 2
cefodizime iv 1.0 4 2
ceftazidime iv 1.0 4 2
cefaclor po 0.5 1 0.5
cefixime po 0.2 1 0.5
cefpodoxime proxetil po 0.2 1 0.5
cefuroxime axetil po 0.5 1 0.5
cefdinir po 0.2 1 0.5
cefetamet pivoxil po 0.5 1 0.5
cefprozil po 0.25 1 0.5
cefotiam hexetil po 0.4 0.5 0.25
ceftibuten po 0.2 1 0.5
cefcamate pivoxil po 0.2 1 0.5
cefteram pivoxil po 0.2 0.5 0.5
cefditoren pivoxii po 0.2 1 0.5
imipenem / cilastatin iv 0.5 1 0.5
aztreonam iv 1.0 4 2
carumonam iv 1.0 4 2
* Chronic respiratory tract infection.
sponse (more than 80% effective). The breakpoints for
some agents, including penicillin G, erythromycin, tet-
racycline and clindamycin could not be determined be-
cause of insufficient or uncertain data.
7. Bacteria-specific breakpoints
The determination of breakpoints for individual bacte-
ria was not attempted in this report. A separate proce-
dure would be necessary in the case of beta-Iactamase
producing bacteria such as Moraxella catarrhalis or
Hemophilus influenzae, methicillin-resistant Staphylococcus
aureus, penicillin-resistant Streptococcus pneumoniae and
anaerobes.
III. CLINICAL BREAKPOINTS IN SEPSIS
1. Subjects and methods
The subjects were elderly patients from one institution
with sepsis due to Pseudomonas aeruginosa or S. aureus.
The measurement of MIC for each organism was per-
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formed by the agar dilution method or microdilution
broth method based on the standard method of the
Japan Society of Chemotherapy. This report focuses
mainly on fJ-Iactam agents, and excludes aminogly-
cosides and new-quinolones due to a lack of sufficient
data.
2. Design of clinical breakpoints in sepsis
The P-M ratio (peak blood concentration one hour af-
ter intravenous administration of the drug/MIC ofbac-
teria) was calculated in individual cases and compared
with the clinical response. The P-M ratio for a clinical
efficacy of80% was defined as the tentative cut-offpoint.
It is assumed that the proposed cut-offpoint be 1.S times
greater, as the real concentration of the drug in the eld-
erly patients is expected to be 1.5 times that of normal
healthy adults.
A clinical response ofalmost 100% was attained in cases
with a P-M ratio of more than 32, decreasing for lesser
values. Although this suggests a tentative breakpoint ofP/
32, the proposed breakpoint was thus modified to P/SO.
Breakpoints in pulmonary infections and sepsis
Table 7. Clinical breakpoints for antimicrobial agents in respiratory tract infections (2).
Group Drug Route Dose (mg) Breakpoint MIC (ug/ml)(single) pneumonia CRTI*
Aminoglycosides gentamicin iv 60 2 2
tobramycin im 60 2 2
dibekacin iv 100 2 2
amikacin im 200 4 4
sisomicin im 75 2 2
micronomicin im 60 2 2
astromicin im 200 4 4
netilmicin im 75 2 2
isepamicin im 200 4 4
arbekacin im 75 2 2
Macrolides rokitamycin po 200 1 1
midecamycin po 400 2 2
roxithromycin po 150 2 2
c1arithromycin po 200 1 2
midecamycin po 600 0.5 0.5
New quinolones norfloxacin po 200 1 1
enoxacin po 200 2 2
ofloxacin po 200 2 2
ciprofloxacin po 200 2 2
tosufloxacin po 150 1 1
lomefloxacin po 200 2 2
temafloxacin po 200 2 4
sparfloxacin po 200 1 2
fleroxacin po 200 2 2
levofloxacin po 100 2 2
Tetracyclines minocycline po 100 1
doxycycl ine po 100 1
* Chronic respiratory tract infection.
Table 8. Clinical breakpoints for antimicrobial agents in sepsis.
Group Drug Route Dose (g) Breakpoint MIC(single) (flg/ml)
Penicillins ampicillin iv 1.0 1
piperacillin iv 2.0 1
ticarcillin iv 1.0 1
aspoxicillin iv 1.0 2
sulbactam / ampicillin i'v 1.5 2
c1avulanic acid /
ticarcillin iv 1.6 2
Cephems cefazolin iv 1.0 2
cefotiam iv 1.0 2
cefoperazone iv 1.0 2
cefmenoxime iv 1.0 2
cefotaxime iv 1.0 1
ceftizoxime iv 1.0 2
cefodizime iv 1.0 2
ceftazidime iv 1.0 2
Carbapenems imipenem / cilastatin iv 0.5 0.5
Monobactams aztreonam iv 1.0 2
carumonam iv 1.0 2
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3. Calculation of breakpoints
The breakpoints in sepsis were determined using the for-
mula constructed for calculating the breakpoints in respi-
ratory infections, but modifying Rtr to 0.5. The proposed
breakpoints in sepsis are listed in Table 8.
It should be cautioned that the proposed breakpoints
are not universal, as our study only considered f3-lactam
antibiotics in elderly patients irrespective of the bacte-
ria involved.
IV. CLOSING REMARKS
The present report constitutes the first attempt in
Japan to determine breakpoints for antimicrobial agents
in pulmonary infections and sepsis. We arrived at the
above points after taking several factors into considera-
tion, such as breakpoint designations (high/low or sen-
sitive/resistant), bacterial species, infection sites.
The formula employed in this report to determine
breakpoints was derived from results of the most cur-
rently reliable test, the double blind test. Consequently,
where information was not available, e.g., for antimi-
crobial agents, such as PCG, EM, CLDM, TC, etc.,
the breakpoints could not be calculated. Breakpoints
are expected to be revised as more reliable basic data
become available. Breakpoints for new antimicrobial
agents will be calculated using the same formula and
reported as these agents are developed.
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